Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

finding that the pill had caused "liver injury" in a study participant earlier this year. Eli Lilly appears to have had far more success, announcing promising Phase 3 trial results last week.

The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It ...

Shanghai-based medical device start-up United InnoMed plans to collaborate with medical institutions in Hong Kong on clinical ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding that the pill had caused "liver injury" in a study participant earlier this year. Eli ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...